Sr. Director/Executive Director - Mass Spectrometry-based Biomarker Discovery - Neuroscience at Eli Lilly and Company

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

PhD in Neuroscience, Biochemistry or a related scientific field
5+ years of experience in biomarker development
Recognized expertise in development of mass spectrometry-based assays for brain diseases

Responsibilities

Lead the development and validation of novel mass spectrometry-based biomarker assays for early- and late-phase clinical trials in neurodegenerative diseases, including Alzheimer’s, Parkinson’s, ALS, and rare brain disorders
Oversee and mentor a team of biomarker researchers at Lilly’s laboratories in Boston, focusing on mass spectrometry-based assay development
Serve as a scientific and technical expert for in-house and outsourced biomarker discovery efforts, guiding experimental study design and analytical strategies
Collaborate cross-functionally with internal stakeholders (medical, operations, statistics, regulatory) and external partners (CROs, academic institutions) to ensure biomarker validation and successful integration into clinical programs
Communicate findings through presentations, publications, and strategic discussions, reinforcing Lilly’s leadership in biomarker innovation

Skills

Mass Spectrometry

Biomarker Discovery

Biomarker Validation

Assay Development

Clinical Trials

Neuroscience

Team Leadership

Proteomics

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free